Monocentric prospective study into the sustained effect of Incobotulinumtoxin A (XEOMIN®) botulinum toxin in chronic refractory migraine

Ioana Ion, Dimitri Renard, Anne Le Floch, Marie De Verdal, Stephane Bouly, Anne Wacongne, Alessandro Lozza, Giovanni Castelnovo

Research output: Contribution to journalArticle

Abstract

Refractory chronic migraine is a disabling disorder impacting quality of life. BOTOX® (Onabotulinumtoxin A) is approved as a prophylactic treatment of chronic migraine in patients unresponsive to at least three prior preventive treatments. The objective of this study was to determine the prophylactic effect of 145 U XEOMIN® (Incobotulinumtoxin A) injected at 31 specific sites in adult patients with refractory chronic migraine. Sixty-one patients (8 men and 53 women, mean age 50) with migraine were recruited, including 20 patients with isolated chronic migraine, 18 patients with chronic migraine associating tension-type headache, 12 patients with migraine associating medication overuse headache, and 11 patients with episodic disabling migraine. The mean number of injections and duration of treatment per patient was 3.5 (range 2–13) and 21 (6–68) months, respectively. From baseline to first injection, 44 patients (73%) had >50% reduction in frequency of migraine episodes, 29 patients (48%) showed >50% reduction in number of headache days, and 28 patients (46%) had a >50% reduction in drug intake. Stable response for all three parameters was observed after the last injection. XEOMIN® thus seems to represent an effective and sustained prophylactic treatment of chronic migraine.

Original languageEnglish
Article number221
JournalToxins
Volume10
Issue number6
DOIs
Publication statusPublished - Jun 1 2018

Keywords

  • Medication overuse headache
  • Prophylactic treatment
  • Refractory chronic migraine
  • Tension headache
  • XEOMIN®

ASJC Scopus subject areas

  • Toxicology
  • Health, Toxicology and Mutagenesis

Fingerprint Dive into the research topics of 'Monocentric prospective study into the sustained effect of Incobotulinumtoxin A (XEOMIN®) botulinum toxin in chronic refractory migraine'. Together they form a unique fingerprint.

  • Cite this